Increased competition in the COPD market.
By Natasha Spiller, Analyst
15 September 2014
I am an Analyst at Datamonitor Healthcare. After joining the company in 2012, I have produced analysis across a number o...
Read full bio
Significant developments in the chronic obstructive pulmonary disease (COPD) market have occurred as numerous new therapies have reached the market or progressed to Phase III trials. Due to the number of product launches, market leaders, like Spiriva, are facing increased competition.
Datamonitor Healthcare has put together detailed analyses of marketed products for COPD across the US, Japan, and five major EU markets, including lifecycle management strategies, new clinical data, and an evaluation of clinical and commercial attributes.
How will our COPD marketed drugs report benefit you?
- Identify market leaders
Understand the developments in COPD as new therapies reach the market and the effect of numerous product launches on current market leaders, allowing you to identify successful products.
- Recognize threats to marketed therapies
Explore how new bronchodilator combinations are directly competing with gold-standard therapy Spiriva and how novel long-acting muscarinic antagonists will compete, enabling you to identify where market share could shift.
- Gain competitive insight
Access detailed analyses of marketed drugs within COPD, including an evaluation of commercial and clinical drug attributes, and a comparison to gold-standard Spiriva, to determine competitiveness in the market.
Key questions answered
- How does the approval of Breo affect GlaxoSmithKline’s presence in the market?
- How will new once-daily therapies and drug classes be positioned in the treatment of COPD?
- How will Boehringer Ingelheim combat competition to its gold-standard therapy Spiriva?
|Drug List:||Companies Mentioned:|
Posted in Respiratory.